Tags

Type your tag names separated by a space and hit enter

Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course.
Mult Scler. 2004 Apr; 10(2):149-52.MS

Abstract

The CCR5 chemokine receptor has been implicated in the pathogenesis of multiple sclerosis (MS). We carried out an allelic association study using a deletion polymorphism in the coding region of the CCR5 gene in 331 relapsing-remitting (RR) and secondary progressive (SP) MS patients, 108 primary progressive (PP) MS patients and 230 healthy controls. Of the 331 RR and SPMS patients, 172 were recruited from specialist clinics and 159 from a population survey. Disease severity was assessed clinically using the Expanded Disability Status Scale (EDSS) and used to calculate a progression index for each patient (defined as EDSS divided by duration of disease). No significant difference in distribution of the CCR5 delta32 allele was observed between the 331 RR/SPMS patients and controls, between the 108 PPMS patients and controls or between the PPMS and RR/SPMS groups. Furthermore, no differences in rate of disease progression were detected between carriers and noncarriers of the delta32 allele. In the population-based group of RR/SPMS patients, carriage of the CCR5 delta32 polymorphism was associated with a lower age at disease onset (mean age 26.562 versus 31.065 years, P = 0.003). However, no significant differences in age of onset were present in the PPMS group or in a second RRMS population. These results suggest that the CCR5 delta32 polymorphism is not a major determinant of susceptibility to develop MS in the population under study, and conflict with a previously reported association between CCR5 delta32 carriage and a better prognosis.

Authors+Show Affiliations

Department of Medical Genetics, Queens University of Belfast, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, Northern Ireland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15124759

Citation

Silversides, J A., et al. "Influence of CCR5 Delta32 Polymorphism On Multiple Sclerosis Susceptibility and Disease Course." Multiple Sclerosis (Houndmills, Basingstoke, England), vol. 10, no. 2, 2004, pp. 149-52.
Silversides JA, Heggarty SV, McDonnell GV, et al. Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course. Mult Scler. 2004;10(2):149-52.
Silversides, J. A., Heggarty, S. V., McDonnell, G. V., Hawkins, S. A., & Graham, C. A. (2004). Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course. Multiple Sclerosis (Houndmills, Basingstoke, England), 10(2), 149-52.
Silversides JA, et al. Influence of CCR5 Delta32 Polymorphism On Multiple Sclerosis Susceptibility and Disease Course. Mult Scler. 2004;10(2):149-52. PubMed PMID: 15124759.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course. AU - Silversides,J A, AU - Heggarty,S V, AU - McDonnell,G V, AU - Hawkins,S A, AU - Graham,C A, PY - 2004/5/6/pubmed PY - 2004/6/4/medline PY - 2004/5/6/entrez SP - 149 EP - 52 JF - Multiple sclerosis (Houndmills, Basingstoke, England) JO - Mult. Scler. VL - 10 IS - 2 N2 - The CCR5 chemokine receptor has been implicated in the pathogenesis of multiple sclerosis (MS). We carried out an allelic association study using a deletion polymorphism in the coding region of the CCR5 gene in 331 relapsing-remitting (RR) and secondary progressive (SP) MS patients, 108 primary progressive (PP) MS patients and 230 healthy controls. Of the 331 RR and SPMS patients, 172 were recruited from specialist clinics and 159 from a population survey. Disease severity was assessed clinically using the Expanded Disability Status Scale (EDSS) and used to calculate a progression index for each patient (defined as EDSS divided by duration of disease). No significant difference in distribution of the CCR5 delta32 allele was observed between the 331 RR/SPMS patients and controls, between the 108 PPMS patients and controls or between the PPMS and RR/SPMS groups. Furthermore, no differences in rate of disease progression were detected between carriers and noncarriers of the delta32 allele. In the population-based group of RR/SPMS patients, carriage of the CCR5 delta32 polymorphism was associated with a lower age at disease onset (mean age 26.562 versus 31.065 years, P = 0.003). However, no significant differences in age of onset were present in the PPMS group or in a second RRMS population. These results suggest that the CCR5 delta32 polymorphism is not a major determinant of susceptibility to develop MS in the population under study, and conflict with a previously reported association between CCR5 delta32 carriage and a better prognosis. SN - 1352-4585 UR - https://www.unboundmedicine.com/medline/citation/15124759/Influence_of_CCR5_delta32_polymorphism_on_multiple_sclerosis_susceptibility_and_disease_course_ L2 - http://journals.sagepub.com/doi/full/10.1191/1352458504ms994oa?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -